Category: by author

Duke sued over Potti case

Anil Potti, courtesy Duke

From the “not terribly surprising” department: Eight patients — or their estates — who enrolled in clinical trials at Duke overseen by Anil Potti and colleagues have sued the university.

The 90-page lawsuit, which names Duke, Potti, Potti’s boss Joseph Nevins, CancerGuide Diagnostics (in which Potti and Nevins had an interest), among others, does a thorough job of documenting the case. In particular, it reviews the history of the trials, which were stopped in 2009, restarted, and then stopped for good as more and more issues came to light. It emphasizes, as you would expect, that Duke and the Potti team were warned repeatedly about problems in their work, notably by Keith Baggerly and a colleague.

Potti and colleagues have, as Retraction Watch readers will remember, now retracted five papers.

The plaintiff’s attorney, Thomas Henson, told Raleigh-Durham’s ABC11: Continue reading Duke sued over Potti case

Publisher error handling two eye papers leads to retractions, new policy on notices

We can only imagine how Joe Hollyfield felt to learn from us, of all people, that his journal, Experimental Eye Research, had retracted two manuscripts in a recent issue.

The papers, “Mechanisms of retinal ganglion cell injury and defense in glaucoma,” by Qu J, Wang D, and Grosskreutz CL, and “Mitochondria: Their role in ganglion cell death and survival in primary open angle glaucoma,” by Osborne, NN, carried the same retraction notices:

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

Because in our experience such unhelpful wording often masks interesting details — read, author misconduct — we called Hollyfield for comment. He graciously walked us through the retractions, explaining the case in detail, until we realized that we were talking about different papers entirely. Hollyfield, it turned out, thought we were asking about the travails of Sangiliyandi Gurunathan, an eye researcher from India whom we’d previously covered and whose work recently had been retracted by Experimental Eye Research and other journals for image manipulation.

But Hollyfield was unaware of the two retractions we’d intended to talk about with him and told us he’d look into them.

Here’s what he learned: Continue reading Publisher error handling two eye papers leads to retractions, new policy on notices

Dutch university investigating psych researcher Stapel for data fraud

Tilburg University in the Netherlands has suspended the prominent social psychologist Diederik Stapel over concerns that he fabricated data in his published studies. According to a translation of a press release from the school, Stapel, professor of cognitive social psychology and dean of Tilburg’s School of Social and Behavioral Sciences, “has committed a serious breach of scientific integrity by using fictitious data in his publications.”

The release says the rector of Tilburg has set up a committee to investigate Stapel’s manuscripts and report back by October. Heading the panel is W.J.M. Levelt, former* president of the Royal Dutch Academy of Sciences and professor emeritus at the Radboud University in Nijmegen.

What the release does not specify, however, is which of Stapel’s many publications — a Medline search comes up with at least 45 bearing his name — are implicated. Continue reading Dutch university investigating psych researcher Stapel for data fraud

Anil Potti failed to disclose corporate ties in yet-to-be-retracted JAMA papers

Anil Potti, the former cancer researcher whose work has become the subject of intense scrutiny that has already led to the retraction of five papers, didn’t tell the Journal of the American Medical Association (JAMA) about two very relevant corporate relationships he had when he published papers there, Retraction Watch has learned.

JAMA has published two papers by Potti and colleagues: 2008’s “Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer,” and 2010’s “Age- and Sex-Specific Genomic Profiles in Non-Small Cell Lung Cancer.”

The Cancer Letter, which has been way out front in the Potti case, first reported Potti’s relationships with Eli Lilly and CancerGuide Diagnostics (formerly Oncogenomics, Inc.). As The Chronicle, Duke’s student newspaper, reported last September, the two companies cut their ties with Potti in July 2010 after allegations of misconduct and lying about a Rhodes Scholarship came to light.

But that was after the two papers were published, and Potti had relationships with both since 2006. As The Chronicle notes, he was a director at CancerGuide Diagnostics (formerly Oncogenomics, Inc.), and Continue reading Anil Potti failed to disclose corporate ties in yet-to-be-retracted JAMA papers

Montreal Heart Institute researcher dismissed following two retractions for image manipulation

A Montreal Heart Institute researcher who retracted two papers less than a month ago has been fired from his post.

Zhiguo Wang, who had been funded by the Canadian Institute of Health Research and the Canadian Diabetes Association, studied the genes linked to heart rhythm abnormalities, among other subjects. Wang also has an appointment at the University of Montreal.

As first reported in Retraction Watch, Wang withdrew two papers for the Journal of Biological Chemistry (JBC) in the journal’s August 12 issue. The story was quickly picked up by Postmedia and the CBC. At the time, Wang told us: Continue reading Montreal Heart Institute researcher dismissed following two retractions for image manipulation

The $240,000 retraction: Scientist responsible gives back company shares

In December, we reported on how a Swedish company that was about to go public dealt with a retraction of a paper in the Proceedings of the National Academy of Sciences (PNAS) that formed some of the basis of their work. The company, Wnt Research, was scheduled to go public on November 26, 2010, but after the retraction appeared on November 11, they postponed the initial public offering (IPO), and let every investor that had expressed an interest know about the retraction.

We thought the company’s moves demonstrated a remarkable transparency. Now we learn that the scientist responsible for the errors that led to the retraction has given back the shares which he or she was given when the company was founded. The company announced the news in a press release last week: Continue reading The $240,000 retraction: Scientist responsible gives back company shares

Imperial committee to weigh “validity” of Ahluwalia’s PhD following second retraction

Earlier this week, we reported on the retraction of another paper by Jatinder Ahluwalia, whose record of misconduct has left marks at Cambridge and University College London. Today, a spokesperson for Imperial College London, where the soon-to-be-retracted work formed the basis of Ahluwalia’s PhD, tells Retraction Watch that a committee will review Ahluwalia’s doctorate: Continue reading Imperial committee to weigh “validity” of Ahluwalia’s PhD following second retraction

Another retraction for Jatinder Ahluwalia, in Journal of Neurochemistry

The Journal of Neurochemistry will retract a paper by Jatinder Ahluwalia, the scientist who recently left his post at the University of East London following an investigation into his work.

Ahluwalia was lead author of the 2003 paper, “Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release,” while earning his PhD at Imperial College London. It had already been the subject of a June 2010 correction. That correction blamed the paper’s problems on a typo:  Continue reading Another retraction for Jatinder Ahluwalia, in Journal of Neurochemistry

New retractions of diabetes, cardiovascular papers from Japan involve repeat use of figures

At least four retractions have appeared involving the work of a group of Japanese researchers who appear to have reused figures — and doctored them — in multiple manuscripts.

The authors, led by Yoshiyuki Hattori, of Dokkyo University School of Medicine in Mibu (whose motto, by the way, is “where character is developed through learning” a reader points out that we had the wrong Dokkyo initially), published the same figure twice, and in the same year, in the Journal of Cardiovascular Pharmacology and Biochimica et Biophysica Acta.

Here’s a retraction notice from the JCP: Continue reading New retractions of diabetes, cardiovascular papers from Japan involve repeat use of figures

A fifth retraction for Anil Potti, this one in Blood

courtesy Duke

The list of papers retracted by former Duke oncologist Anil Potti has grown to five. The notice, from Blood: Continue reading A fifth retraction for Anil Potti, this one in Blood